Eli Lilly Buys Morphic for $3.2B

By Andrew Kessel
Published July 08, 2024
09:44 AM EDT
Eli Lilly

Getty Images

Key Takeaways

  • Eli Lilly said it would buy Morphic for roughly $3.2 billion or $57 per share, a nearly 80% premium to Friday's closing price.
  • Morphic is developing a treatment for inflammatory bowel disease.
  • The deal is expected to close in the third quarter of 2024.

Eli Lilly (LLY) agreed to buy biopharmaceutical firm Morphic (MORF) at a significant premium, sending shares of Morphic skyrocketing Monday.

Eli Lilly said it will pay roughly $3.2 billion for the acquisition, or $57 per share, nearly 80% higher than Morphic’s closing price on Friday. Shares of Morphic surged over 75% in early trading Monday. Eli Lilly shares were little changed. 

Eli Lilly To Gain Morphic Drugs in Development

Morphic’s flagship drug in development for inflammatory bowel disease is known as MORF-057. The treatment is currently involved in a Phase 2 study for treatment of ulcerative colitis and Crohn's disease. 

The Waltham, Mass.-based company is also developing molecules intended to treat autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases, and cancer.

"Oral therapies could open up new possibilities for earlier intervention in diseases like ulcerative colitis, and also provide the potential for combination therapy to help patients with more severe disease," Eli Lilly Chief Scientific Officer Daniel Skovronsky said in a statement. 

The transaction has been approved by the boards of both companies. It is expected to close in the third quarter of 2024.

Do you have a news tip for Investopedia reporters? Please email us at
Article Sources
Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy.

  1. Eli Lilly and Company. “Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease.”

Take the Next Step to Invest
×
The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.